



## Real-World Clinical Evidence of Novel Antibiotics

Guest Editors:

**Dr. Sara Alosaimy**

Anti-Infective Research  
Laboratory, Department of  
Pharmacy Practice, Eugene  
Applebaum College of Pharmacy  
and Health Sciences, Wayne  
State University, Detroit, MI, USA

**Prof. Dr. Antonio Cascio**

Department of Health  
Promotion, Mother and Child  
Care, Internal Medicine and  
Medical Specialties, University of  
Palermo, Palermo, Italy

Deadline for manuscript  
submissions:

**closed (15 November 2022)**

### Message from the Guest Editors

Dear Colleagues,

Several novel antibiotics were developed in the past 10 years to combat multi-drug resistant pathogens. They were approved upon randomized clinical trials (RCT) to demonstrate the efficacy and safety for a specific infection in a controlled environment. On the other hand, real-world evidence (RWE) in the form of post-marketing studies can help to evaluate how the novel antibiotic performs in a diverse population outside of that assessed in RCT. They aim to bridge the gap between clinical trials and routine clinical practice.

In this Special Issue, we aim to RWE of antimicrobials in a diverse, challenging patient population that are not commonly represented in RCT such as elderly, non-approved indications, those with augmented renal clearance, as well immunocompromised patients. RWE includes registries, case series, and comparative studies.

This fits the scope of antibiotics because it adds to the existing evidence regarding the use of novel antibiotics.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

## Contact Us

*Antibiotics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/antibiotics](http://mdpi.com/journal/antibiotics)  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)  
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)